A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Phase 4 Completed 97 enrolled Pharmacosmos A/S

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease and comparison of the incidence of hypophosphatemia

Timeline

Start: 2018-05-23
Primary completion: 2020-05-25
Completion: 2020-05-25

Publications

Bjorner JB, Kennedy N, Lindgren S, Pollock RF. Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease. Qual Life Res. 2024 Aug;33(8):2285-2294. doi: 10.1007/s11136-024-03642-y. Epub 2024 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ferric carboxymaltose	Other / unclassified	—	Intravenous
Subject	Iron isomaltoside 1000	Unknown	—	Intravenous

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Summary

Timeline

Publications

Drugs

Indications